Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs.

Soncini D, Orecchioni S, Ruberti S, Minetto P, Martinuzzi C, Agnelli L, Todoerti K, Cagnetta A, Miglino M, Clavio M, Contini P, Varaldo R, Bergamaschi M, Guolo F, Passalacqua M, Nencioni A, Monacelli F, Gobbi M, Neri A, Abbadessa G, Eathiraj S, Schwartz B, Bertolini F, Lemoli RM, Cea M.

Haematologica. 2019 Oct 17. pii: haematol.2019.224956. doi: 10.3324/haematol.2019.224956. [Epub ahead of print]

2.

Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma.

Taiana E, Favasuli V, Ronchetti D, Todoerti K, Pelizzoni F, Manzoni M, Barbieri M, Fabris S, Silvestris I, Gallo Cantafio ME, Platonova N, Zuccalà V, Maltese L, Soncini D, Ruberti S, Cea M, Chiaramonte R, Amodio N, Tassone P, Agnelli L, Neri A.

Leukemia. 2019 Aug 19. doi: 10.1038/s41375-019-0542-5. [Epub ahead of print]

PMID:
31427718
3.

Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.

Cagnetta A, Soncini D, Orecchioni S, Talarico G, Minetto P, Guolo F, Retali V, Colombo N, Carminati E, Clavio M, Miglino M, Bergamaschi M, Nahimana A, Duchosal M, Todoerti K, Neri A, Passalacqua M, Bruzzone S, Nencioni A, Bertolini F, Gobbi M, Lemoli RM, Cea M.

Haematologica. 2018 Jan;103(1):80-90. doi: 10.3324/haematol.2017.176248. Epub 2017 Oct 12.

4.

SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects.

Damonte P, Sociali G, Parenti MD, Soncini D, Bauer I, Boero S, Grozio A, Holtey MV, Piacente F, Becherini P, Sanguineti R, Salis A, Damonte G, Cea M, Murone M, Poggi A, Nencioni A, Del Rio A, Bruzzone S.

Bioorg Med Chem. 2017 Oct 15;25(20):5849-5858. doi: 10.1016/j.bmc.2017.09.023. Epub 2017 Sep 19.

PMID:
28958848
5.

Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies.

Cea M, Soncini D, Gobbi M, Lemoli RM, Cagnetta A.

Expert Rev Anticancer Ther. 2016 Sep;16(9):897-8. doi: 10.1080/14737140.2016.1212664. Epub 2016 Jul 22. No abstract available.

PMID:
27433930
6.

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.

Cea M, Cagnetta A, Acharya C, Acharya P, Tai YT, Yang C, Lovera D, Soncini D, Miglino M, Fraternali-Orcioni G, Mastracci L, Nencioni A, Montecucco F, Monacelli F, Ballestrero A, Hideshima T, Chauhan D, Gobbi M, Lemoli RM, Munshi N, Treon SP, Anderson KC.

Clin Cancer Res. 2016 Dec 15;22(24):6099-6109. Epub 2016 Jun 10.

7.

Synthesis and biological characterization of 3-(imidazol-1-ylmethyl)piperidine sulfonamides as aromatase inhibitors.

Di Matteo M, Ammazzalorso A, Andreoli F, Caffa I, De Filippis B, Fantacuzzi M, Giampietro L, Maccallini C, Nencioni A, Parenti MD, Soncini D, Del Rio A, Amoroso R.

Bioorg Med Chem Lett. 2016 Jul 1;26(13):3192-3194. doi: 10.1016/j.bmcl.2016.04.078. Epub 2016 Apr 28.

PMID:
27161804
8.

EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.

Zucal C, D'Agostino VG, Casini A, Mantelli B, Thongon N, Soncini D, Caffa I, Cea M, Ballestrero A, Quattrone A, Indraccolo S, Nencioni A, Provenzani A.

BMC Cancer. 2015 Nov 5;15:855. doi: 10.1186/s12885-015-1845-1.

9.

APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells.

Cagnetta A, Caffa I, Acharya C, Soncini D, Acharya P, Adamia S, Pierri I, Bergamaschi M, Garuti A, Fraternali G, Mastracci L, Provenzani A, Zucal C, Damonte G, Salis A, Montecucco F, Patrone F, Ballestrero A, Bruzzone S, Gobbi M, Nencioni A, Cea M.

Clin Cancer Res. 2015 Sep 1;21(17):3934-45. doi: 10.1158/1078-0432.CCR-14-3023. Epub 2015 May 11.

10.

Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition.

Caffa I, D'Agostino V, Damonte P, Soncini D, Cea M, Monacelli F, Odetti P, Ballestrero A, Provenzani A, Longo VD, Nencioni A.

Oncotarget. 2015 May 20;6(14):11820-32.

11.

Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.

Soncini D, Caffa I, Zoppoli G, Cea M, Cagnetta A, Passalacqua M, Mastracci L, Boero S, Montecucco F, Sociali G, Lasigliè D, Damonte P, Grozio A, Mannino E, Poggi A, D'Agostino VG, Monacelli F, Provenzani A, Odetti P, Ballestrero A, Bruzzone S, Nencioni A.

J Biol Chem. 2014 Dec 5;289(49):34189-204. doi: 10.1074/jbc.M114.594721. Epub 2014 Oct 20.

12.

Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques.

Fraga-Silva RA, Savergnini SQ, Montecucco F, Nencioni A, Caffa I, Soncini D, Costa-Fraga FP, De Sousa FB, Sinisterra RD, Capettini LA, Lenglet S, Galan K, Pelli G, Bertolotto M, Pende A, Spinella G, Pane B, Dallegri F, Palombo D, Mach F, Stergiopulos N, Santos RA, da Silva RF.

Thromb Haemost. 2014 Apr 1;111(4):736-47. doi: 10.1160/TH13-06-0448. Epub 2014 Feb 6.

PMID:
24499778
13.

Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice.

Braunersreuther V, Montecucco F, Pelli G, Galan K, Proudfoot AE, Belin A, Vuilleumier N, Burger F, Lenglet S, Caffa I, Soncini D, Nencioni A, Vallée JP, Mach F.

Thromb Haemost. 2013 Oct;110(4):807-25. doi: 10.1160/TH13-04-0297. Epub 2013 Aug 8.

PMID:
23925450
14.

CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.

Grozio A, Sociali G, Sturla L, Caffa I, Soncini D, Salis A, Raffaelli N, De Flora A, Nencioni A, Bruzzone S.

J Biol Chem. 2013 Sep 6;288(36):25938-49. doi: 10.1074/jbc.M113.470435. Epub 2013 Jul 23.

15.

Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience.

Montecucco F, Cea M, Bauer I, Soncini D, Caffa I, Lasigliè D, Nahimana A, Uccelli A, Bruzzone S, Nencioni A.

Curr Drug Targets. 2013 Jun 1;14(6):637-43. Review.

PMID:
23531116
16.

The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses.

Bauer I, Grozio A, Lasigliè D, Basile G, Sturla L, Magnone M, Sociali G, Soncini D, Caffa I, Poggi A, Zoppoli G, Cea M, Feldmann G, Mostoslavsky R, Ballestrero A, Patrone F, Bruzzone S, Nencioni A.

J Biol Chem. 2012 Nov 30;287(49):40924-37. doi: 10.1074/jbc.M112.405837. Epub 2012 Oct 18.

17.

Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer.

Soncini D, Caffa I, Patrone F, Ballestrero A, Nencioni A.

Curr Cancer Drug Targets. 2012 May;12(4):329-38. Review.

PMID:
22385509
18.

Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells.

Cea M, Soncini D, Fruscione F, Raffaghello L, Garuti A, Emionite L, Moran E, Magnone M, Zoppoli G, Reverberi D, Caffa I, Salis A, Cagnetta A, Bergamaschi M, Casciaro S, Pierri I, Damonte G, Ansaldi F, Gobbi M, Pistoia V, Ballestrero A, Patrone F, Bruzzone S, Nencioni A.

PLoS One. 2011;6(7):e22739. doi: 10.1371/journal.pone.0022739. Epub 2011 Jul 27.

19.

Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.

Zoppoli G, Cea M, Soncini D, Fruscione F, Rudner J, Moran E, Caffa I, Bedognetti D, Motta G, Ghio R, Ferrando F, Ballestrero A, Parodi S, Belka C, Patrone F, Bruzzone S, Nencioni A.

Exp Hematol. 2010 Nov;38(11):979-88. doi: 10.1016/j.exphem.2010.07.013. Epub 2010 Aug 7.

PMID:
20696207
20.

Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental results.

Castagnino N, Tortolina L, Balbi A, Pesenti R, Montagna R, Ballestrero A, Soncini D, Moran E, Nencioni A, Parodi S.

Curr Cancer Drug Targets. 2010 Nov;10(7):737-57.

PMID:
20578981
21.

Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.

Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, Moran E, Zoppoli G, Pistoia V, Patrone F, Ballestrero A.

PLoS One. 2010 Feb 2;5(2):e9024. doi: 10.1371/journal.pone.0009024.

22.

Ras-induced resistance to lapatinib is overcome by MEK inhibition.

Zoppoli G, Moran E, Soncini D, Cea M, Garuti A, Rocco I, Cirmena G, Grillo V, Bagnasco L, Icardi G, Ansaldi F, Parodi S, Patrone F, Ballestrero A, Nencioni A.

Curr Cancer Drug Targets. 2010 Mar;10(2):168-75.

PMID:
20088787
23.

Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.

Bruzzone S, Fruscione F, Morando S, Ferrando T, Poggi A, Garuti A, D'Urso A, Selmo M, Benvenuto F, Cea M, Zoppoli G, Moran E, Soncini D, Ballestrero A, Sordat B, Patrone F, Mostoslavsky R, Uccelli A, Nencioni A.

PLoS One. 2009 Nov 19;4(11):e7897. doi: 10.1371/journal.pone.0007897.

24.

Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.

Balza E, Carnemolla B, Mortara L, Castellani P, Soncini D, Accolla RS, Borsi L.

Int J Cancer. 2010 Jul 1;127(1):101-10. doi: 10.1002/ijc.25018.

Supplemental Content

Loading ...
Support Center